4.419 – Vaccine and Immunotherapy Delivery

[1]  R. Lai,et al.  Development of a poly(d,l-lactic-co-glycolic acid) nanoparticle formulation of STAT3 inhibitor JSI-124: implication for cancer immunotherapy. , 2010, Molecular pharmaceutics.

[2]  S. Akira,et al.  Pattern Recognition Receptors and Inflammation , 2010, Cell.

[3]  R. Webby,et al.  Dynamic T cell migration program provides resident memory within intestinal epithelium , 2010, The Journal of experimental medicine.

[4]  B. Walker,et al.  Immunology and the elusive AIDS vaccine , 2010, Nature.

[5]  T. Park,et al.  Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers. , 2010, Biomaterials.

[6]  S. Amigorena,et al.  Intracellular mechanisms of antigen cross presentation in dendritic cells. , 2010, Current opinion in immunology.

[7]  A. Iwasaki,et al.  Regulation of Adaptive Immunity by the Innate Immune System , 2010, Science.

[8]  Joseph D. Smith,et al.  Advances and challenges in malaria vaccine development , 2009, Expert Reviews in Molecular Medicine.

[9]  Jeffrey A. Hubbell,et al.  Materials engineering for immunomodulation , 2009, Nature.

[10]  Daniel G. Anderson,et al.  Nanoparticle-Delivered Multimeric Soluble CD40L DNA Combined with Toll-Like Receptor Agonists as a Treatment for Melanoma , 2009, PloS one.

[11]  Ashutosh Kumar Singh,et al.  In-situ crosslinking hydrogels for combinatorial delivery of chemokines and siRNA-DNA carrying microparticles to dendritic cells. , 2009, Biomaterials.

[12]  Elizabeth E Gray,et al.  Immune complex relay by subcapsular sinus macrophages and non-cognate B cells drives antibody affinity maturation , 2009, Nature Immunology.

[13]  E. De Gregorio,et al.  Mechanism of action of licensed vaccine adjuvants. , 2009, Vaccine.

[14]  C. Liu,et al.  Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. , 2009, Vaccine.

[15]  Richard A Flavell,et al.  Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. , 2009, Vaccine.

[16]  R. Gao,et al.  Promotion of immunity of mice to Pasteurella multocida and hog cholera vaccine by pig interleukin-6 gene and CpG motifs. , 2009, Comparative immunology, microbiology and infectious diseases.

[17]  P. Marrack,et al.  Towards an understanding of the adjuvant action of aluminium , 2009, Nature Reviews Immunology.

[18]  Ying K. Tam,et al.  Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy. , 2009, Advanced drug delivery reviews.

[19]  Manmohan J. Singh,et al.  Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles. , 2009, Advanced drug delivery reviews.

[20]  F. Martinon,et al.  The inflammasomes: guardians of the body. , 2009, Annual review of immunology.

[21]  Cécile Chalouni,et al.  Chitin Is a Size-Dependent Regulator of Macrophage TNF and IL-10 Production1 , 2009, The Journal of Immunology.

[22]  Hua Yu,et al.  Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy. , 2009, Cancer research.

[23]  Manmohan J. Singh,et al.  MF59 Emulsion Is an Effective Delivery System for a Synthetic TLR4 Agonist (E6020) , 2009, Pharmaceutical Research.

[24]  T. Baumert,et al.  Development of hepatitis C virus vaccines: challenges and progress , 2009, Expert review of vaccines.

[25]  J. Kohlmeier,et al.  Migration, maintenance and recall of memory T cells in peripheral tissues , 2009, Nature Reviews Immunology.

[26]  Daniel G. Anderson,et al.  Polymeric Materials for Gene Delivery and DNA Vaccination , 2009, Advanced materials.

[27]  Tsuneji Nagai,et al.  PEG–PLA diblock copolymer micelle-like nanoparticles as all-trans-retinoic acid carrier: in vitro and in vivo characterizations , 2009, Nanotechnology.

[28]  Bali Pulendran,et al.  The stimulation of CD8+ T cells by dendritic cells pulsed with polyketal microparticles containing ion-paired protein antigen and poly(inosinic acid)-poly(cytidylic acid). , 2009, Biomaterials.

[29]  John Samuel,et al.  Self-associating poly(ethylene oxide)-b-poly(alpha-cholesteryl carboxylate-epsilon-caprolactone) block copolymer for the solubilization of STAT-3 inhibitor cucurbitacin I. , 2009, Biomacromolecules.

[30]  J. Tschopp,et al.  Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome , 2009, Proceedings of the National Academy of Sciences.

[31]  David J. Mooney,et al.  Infection-Mimicking Materials to Program Dendritic Cells In Situ , 2008, Nature materials.

[32]  V. Cerundolo,et al.  Harnessing invariant NKT cells in vaccination strategies , 2009, Nature Reviews Immunology.

[33]  D. Mooney,et al.  Sustained GM-CSF and PEI condensed pDNA presentation increases the level and duration of gene expression in dendritic cells. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[34]  F. Caruso,et al.  Binding, Internalization, and Antigen Presentation of Vaccine‐Loaded Nanoengineered Capsules in Blood , 2008 .

[35]  Karan Sharma,et al.  Receptor-independent, direct membrane binding leads to cell-surface lipid sorting and Syk kinase activation in dendritic cells. , 2008, Immunity.

[36]  Rino Rappuoli,et al.  Alum adjuvanticity: Unraveling a century old mystery , 2008, European journal of immunology.

[37]  K. Rock,et al.  Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization , 2008, Nature Immunology.

[38]  R. Rappuoli,et al.  Molecular and cellular signatures of human vaccine adjuvants , 2008, Proceedings of the National Academy of Sciences.

[39]  F. Re,et al.  Cutting Edge: Inflammasome Activation by Alum and Alum’s Adjuvant Effect Are Mediated by NLRP31 , 2008, The Journal of Immunology.

[40]  K. S. Jones.  Biomaterials as vaccine adjuvants , 2008, Biotechnology progress.

[41]  Richard A. Flavell,et al.  Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants , 2008, Nature.

[42]  L. Santambrogio,et al.  Immunogenecity of Modified Alkane Polymers Is Mediated through TLR1/2 Activation , 2008, PloS one.

[43]  G. Besra,et al.  B cell receptor-mediated uptake of CD1d-restricted antigen augments antibody responses by recruiting invariant NKT cell help in vivo , 2008, Proceedings of the National Academy of Sciences.

[44]  H. Junginger,et al.  Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[45]  Hong Zhou,et al.  Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders. , 2008, Vaccine.

[46]  Mariagrazia Pizza,et al.  The Adjuvants Aluminum Hydroxide and MF59 Induce Monocyte and Granulocyte Chemoattractants and Enhance Monocyte Differentiation toward Dendritic Cells1 , 2008, The Journal of Immunology.

[47]  Henk C. Hoogsteden,et al.  Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells , 2008, The Journal of experimental medicine.

[48]  J. Babensee.  Interaction of dendritic cells with biomaterials. , 2008, Seminars in immunology.

[49]  F. Marincola,et al.  Tumour immunity: effector response to tumour and role of the microenvironment , 2008, The Lancet.

[50]  Manmohan J. Singh,et al.  The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles. , 2008, Journal of pharmaceutical sciences.

[51]  S. Holgate,et al.  Treatment strategies for allergy and asthma , 2008, Nature Reviews Immunology.

[52]  C. Russell Middaugh,et al.  Nanotechnology in vaccine delivery☆ , 2008, Advanced Drug Delivery Reviews.

[53]  L. Harrison.  Vaccination against self to prevent autoimmune disease: the type 1 diabetes model , 2008, Immunology and cell biology.

[54]  A. Khamesipour,et al.  Coencapsulation of CpG Oligodeoxynucleotides with Recombinant Leishmania major Stress-Inducible Protein 1 in Liposome Enhances Immune Response and Protection against Leishmaniasis in Immunized BALB/c Mice , 2008, Clinical and Vaccine Immunology.

[55]  R. Rappuoli,et al.  Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. , 2008, Vaccine.

[56]  Roberta Baronio,et al.  Introduction of Zwitterionic Motifs into Bacterial Polysaccharides Generates TLR2 Agonists Able to Activate APCs , 2007, The Journal of Immunology.

[57]  T. Murphy,et al.  Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. , 2007, JAMA.

[58]  N. D. Di Paolo,et al.  Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells , 2007, Nature.

[59]  Y. Bae,et al.  Self-assembled polyethylenimine-graft-poly(ε-caprolactone) micelles as potential dual carriers of genes and anticancer drugs , 2007 .

[60]  Aravind Chakrapani,et al.  Nanoparticles and microparticles as vaccine-delivery systems , 2007, Expert review of vaccines.

[61]  Sai T Reddy,et al.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.

[62]  R. Steinman,et al.  Taking dendritic cells into medicine , 2007, Nature.

[63]  Darrell J Irvine,et al.  Cytosolic delivery of membrane-impermeable molecules in dendritic cells using pH-responsive core-shell nanoparticles. , 2007, Nano letters.

[64]  D. Busch,et al.  Antigen co‐encapsulated with adjuvants efficiently drive protective T cell immunity , 2007, European journal of immunology.

[65]  F. Batista,et al.  B cells acquire particulate antigen in a macrophage-rich area at the boundary between the follicle and the subcapsular sinus of the lymph node. , 2007, Immunity.

[66]  A. Saul,et al.  Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen. , 2007, Vaccine.

[67]  M. Jenkins,et al.  CCR6-dependent recruitment of blood phagocytes is necessary for rapid CD4 T cell responses to local bacterial infection , 2007, Proceedings of the National Academy of Sciences.

[68]  S. Kawakami,et al.  Development of an antigen-presenting cell-targeted DNA vaccine against melanoma by mannosylated liposomes. , 2007, Biomaterials.

[69]  B. Guy,et al.  The perfect mix: recent progress in adjuvant research , 2007, Nature Reviews Microbiology.

[70]  S. Vyas,et al.  Implication of nanoparticles/microparticles in mucosal vaccine delivery , 2007, Expert review of vaccines.

[71]  A. Alshamsan,et al.  Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D,L-lactic-co-glycolic acid) nanoparticles. , 2007, Journal of biomedical materials research. Part A.

[72]  M. Jenkins,et al.  The humoral immune response is initiated in lymph nodes by B cells that acquire soluble antigen directly in the follicles. , 2007, Immunity.

[73]  F. Re,et al.  Aluminum Hydroxide Adjuvants Activate Caspase-1 and Induce IL-1β and IL-18 Release1 , 2007, The Journal of Immunology.

[74]  M. Guenounou,et al.  Involvement of toll-like receptor 4 in the inflammatory reaction induced by hydroxyapatite particles. , 2007, Biomaterials.

[75]  S. Mariathasan,et al.  Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation , 2007, Nature Reviews Immunology.

[76]  Bo Nilsson,et al.  The role of complement in biomaterial-induced inflammation. , 2007, Molecular immunology.

[77]  Bushra Zaidi,et al.  TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines , 2007, Cancer Immunology, Immunotherapy.

[78]  A. Zimmer,et al.  Immunostimulatory properties of CpG-oligonucleotides are enhanced by the use of protamine nanoparticles. , 2006, Oligonucleotides.

[79]  J. Sattabongkot,et al.  A Novel Chimeric Plasmodium vivax Circumsporozoite Protein Induces Biologically Functional Antibodies That Recognize both VK210 and VK247 Sporozoites , 2006, Infection and Immunity.

[80]  B. Tesar,et al.  The Role of Hyaluronan Degradation Products as Innate Alloimmune Agonists , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[81]  Ho Sup Yoon,et al.  Co-delivery of drugs and DNA from cationic core–shell nanoparticles self-assembled from a biodegradable copolymer , 2006, Nature materials.

[82]  J. Altin,et al.  Liposomal vaccines--targeting the delivery of antigen. , 2006, Methods.

[83]  M. Houghton,et al.  Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. , 2006, The Journal of general virology.

[84]  Jean-Pierre Benoit,et al.  Parameters influencing the stealthiness of colloidal drug delivery systems. , 2006, Biomaterials.

[85]  M. Horton,et al.  Hyaluronan Fragments Act as an Endogenous Danger Signal by Engaging TLR21 , 2006, The Journal of Immunology.

[86]  Ronald N. Germain,et al.  Extrafollicular Activation of Lymph Node B Cells by Antigen-Bearing Dendritic Cells , 2006, Science.

[87]  S. Dow,et al.  Efficient Immunization and Cross-Priming by Vaccine Adjuvants Containing TLR3 or TLR9 Agonists Complexed to Cationic Liposomes1 , 2006, The Journal of Immunology.

[88]  K. Leong,et al.  Enhancing efficacy of HIV gag DNA vaccine by local delivery of GM-CSF in murine and macaque models. , 2006, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[89]  Sai T Reddy,et al.  In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[90]  R. Kontermann,et al.  Cytotoxic T Lymphocytes Responding to Low Dose TRP2 Antigen are Induced Against B16 Melanoma by Liposome-encapsulated TRP2 Peptide and CpG DNA Adjuvant , 2006, Journal of immunotherapy.

[91]  J. Mora,et al.  T-cell homing specificity and plasticity: new concepts and future challenges. , 2006, Trends in immunology.

[92]  R. Medzhitov,et al.  Toll-dependent selection of microbial antigens for presentation by dendritic cells , 2006, Nature.

[93]  P. Boros,et al.  New Cellular and Molecular Immune Pathways in Ischemia/Reperfusion Injury , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[94]  Samir Mitragotri,et al.  Role of target geometry in phagocytosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[95]  Thierry Boon,et al.  Human T cell responses against melanoma. , 2006, Annual review of immunology.

[96]  Balaji Narasimhan,et al.  Single dose vaccine based on biodegradable polyanhydride microspheres can modulate immune response mechanism. , 2006, Journal of biomedical materials research. Part A.

[97]  Yue Zhang,et al.  An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen. , 2006, International immunology.

[98]  Manmohan J. Singh,et al.  Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[99]  T. Vogel,et al.  Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100 , 2006, Cancer.

[100]  J. Brewer.  (How) do aluminium adjuvants work? , 2006, Immunology letters.

[101]  P. Cresswell,et al.  Enhanced and prolonged cross‐presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles , 2006, Immunology.

[102]  S. Moghimi,et al.  The effect of methoxy-PEG chain length and molecular architecture on lymph node targeting of immuno-PEG liposomes. , 2006, Biomaterials.

[103]  J. Bystryn,et al.  Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice , 2006, Cancer Immunology, Immunotherapy.

[104]  N. Shastri,et al.  In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[105]  Samir Mitragotri,et al.  Immunization without needles , 2005, Nature Reviews Immunology.

[106]  S. Kasturi,et al.  Covalent conjugation of polyethyleneimine on biodegradable microparticles for delivery of plasmid DNA vaccines. , 2005, Biomaterials.

[107]  G. Prestwich,et al.  Regulation of lung injury and repair by Toll-like receptors and hyaluronan , 2005, Nature Medicine.

[108]  N. Murthy,et al.  Polyketal nanoparticles: a new pH-sensitive biodegradable drug delivery vehicle. , 2005, Bioconjugate chemistry.

[109]  J. Babensee,et al.  Differential levels of dendritic cell maturation on different biomaterials used in combination products. , 2005, Journal of biomedical materials research. Part A.

[110]  L. Babiuk,et al.  Microparticles for oral delivery of vaccines , 2005, Expert opinion on drug delivery.

[111]  D. Irvine,et al.  Synthesis of protein-loaded hydrogel particles in an aqueous two-phase system for coincident antigen and CpG oligonucleotide delivery to antigen-presenting cells. , 2005, Biomacromolecules.

[112]  D. Irvine,et al.  Directed cell migration via chemoattractants released from degradable microspheres. , 2005, Biomaterials.

[113]  Melody A. Swartz,et al.  Dendritic-cell trafficking to lymph nodes through lymphatic vessels , 2005, Nature Reviews Immunology.

[114]  Alimuddin Zumla,et al.  Immune responses to tuberculosis in developing countries: implications for new vaccines , 2005, Nature Reviews Immunology.

[115]  D. Montefiori,et al.  Enhanced Potency of Plasmid DNA Microparticle Human Immunodeficiency Virus Vaccines in Rhesus Macaques by Using a Priming-Boosting Regimen with Recombinant Proteins , 2005, Journal of Virology.

[116]  J. Babensee,et al.  The effect of the physical form of poly(lactic-co-glycolic acid) carriers on the humoral immune response to co-delivered antigen. , 2005, Biomaterials.

[117]  Mark J. Miller,et al.  Antigen-Engaged B Cells Undergo Chemotaxis toward the T Zone and Form Motile Conjugates with Helper T Cells , 2005, PLoS biology.

[118]  Henry C. Chang,et al.  Differential Lysosomal Proteolysis in Antigen-Presenting Cells Determines Antigen Fate , 2005, Science.

[119]  J. Paul Robinson,et al.  Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. , 2005, Vaccine.

[120]  I. Frazer,et al.  Activation of dendritic cells by human papillomavirus‐like particles through TLR4 and NF‐κB‐mediated signalling, moderated by TGF‐β , 2005 .

[121]  B. Ivins,et al.  CpG Oligodeoxynucleotides Adsorbed onto Polylactide-Co-Glycolide Microparticles Improve the Immunogenicity and Protective Activity of the Licensed Anthrax Vaccine , 2005, Infection and Immunity.

[122]  John Samuel,et al.  Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[123]  J. Mora,et al.  Reciprocal and dynamic control of CD8 T cell homing by dendritic cells from skin- and gut-associated lymphoid tissues , 2005, The Journal of experimental medicine.

[124]  Y. Perrie,et al.  Particulate delivery systems for vaccines. , 2005, Critical reviews in therapeutic drug carrier systems.

[125]  Manmohan J. Singh,et al.  Adsorption of a Novel Recombinant Glycoprotein from HIV (Env gp120dV2 SF162) to Anionic PLG Microparticles Retains the Structural Integrity of the Protein, Whereas Encapsulation in PLG Microparticles Does Not , 2004, Pharmaceutical Research.

[126]  S. Akira,et al.  Liposome-Encapsulated CpG Oligodeoxynucleotides as a Potent Adjuvant for Inducing Type 1 Innate Immunity , 2004, Cancer Research.

[127]  M. Plebanski,et al.  Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice. , 2004, Vaccine.

[128]  Praveen Elamanchili,et al.  Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery. , 2004, Current drug delivery.

[129]  D. Price,et al.  CD4+ T Cell Depletion during all Stages of HIV Disease Occurs Predominantly in the Gastrointestinal Tract , 2004, The Journal of experimental medicine.

[130]  E. B. Lindblad.  Aluminium adjuvants--in retrospect and prospect. , 2004, Vaccine.

[131]  Jie Li,et al.  Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors1 , 2004, The Journal of Immunology.

[132]  D. Dormont,et al.  Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. , 2004, Vaccine.

[133]  Ruth Duncan,et al.  Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation , 2004, Nature Biotechnology.

[134]  I. Frazer,et al.  Despite differences between dendritic cells and Langerhans cells in the mechanism of papillomavirus-like particle antigen uptake, both cells cross-prime T cells. , 2004, Virology.

[135]  Daniel G. Anderson,et al.  Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[136]  B. Gander,et al.  In vivo uptake of an experimental microencapsulated diphtheria vaccine following sub-cutaneous immunisation. , 2004, Vaccine.

[137]  P. Marrack,et al.  Promotion of B Cell Immune Responses via an Alum-Induced Myeloid Cell Population , 2004, Science.

[138]  C. Demangel,et al.  Targeting Dendritic Cells with Antigen-Containing Liposomes , 2004, Cancer Research.

[139]  Jack A. Elias,et al.  Acidic Mammalian Chitinase in Asthmatic Th2 Inflammation and IL-13 Pathway Activation , 2004, Science.

[140]  X. Jiao,et al.  Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes. , 2004, The Journal of general virology.

[141]  Polly Matzinger,et al.  Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses , 2004, Nature Reviews Immunology.

[142]  D. Pardoll,et al.  Persistent Toll-like receptor signals are required for reversal of regulatory T cell–mediated CD8 tolerance , 2004, Nature Immunology.

[143]  N. Murthy,et al.  Cross-linked microparticles as carriers for the delivery of plasmid DNA for vaccine development. , 2004, Bioconjugate chemistry.

[144]  Manmohan J. Singh,et al.  Charged polylactide co-glycolide microparticles as antigen delivery systems , 2004, Expert opinion on biological therapy.

[145]  R. Steinman,et al.  In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination , 2004, The Journal of experimental medicine.

[146]  Qing Ge,et al.  Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines , 2004, Nature materials.

[147]  J. Donnelly,et al.  Cationic Microparticles Are an Effective Delivery System for Immune Stimulatory CpG DNA , 2001, Pharmaceutical Research.

[148]  Lisbeth Illum,et al.  Preparation of Biodegradable, Surface Engineered PLGA Nanospheres with Enhanced Lymphatic Drainage and Lymph Node Uptake , 1997, Pharmaceutical Research.

[149]  T. Uchida,et al.  Dose and Load Studies for Subcutaneous and Oral Delivery of Poly(lactide-co-glycolide) Microspheres Containing Ovalbumin , 1994, Pharmaceutical Research.

[150]  J. Babensee,et al.  Humoral immune responses to model antigen co-delivered with biomaterials used in tissue engineering. , 2004, Biomaterials.

[151]  D. Crommelin,et al.  Liposomes Containing Interferon-Gamma as Adjuvant in Tumor Cell Vaccines , 2004, Pharmaceutical Research.

[152]  D. McDonald,et al.  Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles. , 2003, Cellular immunology.

[153]  R. Koup,et al.  Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates , 2003, Nature.

[154]  D. Schadendorf,et al.  Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen. , 2003, Blood.

[155]  V. Kouskoff,et al.  Visualization of the Genesis and Fate of Isotype-switched B Cells during a Primary Immune Response , 2003, The Journal of experimental medicine.

[156]  Jean M. J. Fréchet,et al.  A macromolecular delivery vehicle for protein-based vaccines: Acid-degradable protein-loaded microgels , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[157]  S. Moghimi.  Modulation of lymphatic distribution of subcutaneously injected poloxamer 407‐coated nanospheres: the effect of the ethylene oxide chain configuration , 2003, FEBS letters.

[158]  Praveen Elamanchili,et al.  Biodegradable Nanoparticle Mediated Antigen Delivery to Human Cord Blood Derived Dendritic Cells for Induction of Primary T Cell Responses , 2003, Journal of drug targeting.

[159]  M. Tafaghodi,et al.  Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[160]  Jayanth Panyam,et al.  Rapid endo‐lysosomal escape of poly(DL‐lactide‐coglycolide) nanoparticles: implications for drug and gene delivery , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[161]  G. Kwon,et al.  Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. , 2002, Journal of biomedical materials research.

[162]  T. Ahrens,et al.  Oligosaccharides of Hyaluronan Activate Dendritic Cells via Toll-like Receptor 4 , 2002, The Journal of experimental medicine.

[163]  H. Matsue,et al.  Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine , 2002, Nature Biotechnology.

[164]  K. Ishii,et al.  Sterically Stabilized Cationic Liposomes Improve the Uptake and Immunostimulatory Activity of CpG Oligonucleotides1 , 2001, The Journal of Immunology.

[165]  G. Storm,et al.  Liposomes to target the lymphatics by subcutaneous administration. , 2001, Advanced drug delivery reviews.

[166]  David J Brayden,et al.  Microparticle vaccine approaches to stimulate mucosal immunisation. , 2001, Microbes and infection.

[167]  Y. Y. Yang,et al.  POE-PEG-POE triblock copolymeric microspheres containing protein. I. Preparation and characterization. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[168]  Robert Langer,et al.  pH-Responsive Polymer Microspheres: Rapid Release of Encapsulated Material within the Range of Intracellular pH** , 2001 .

[169]  G. Ott,et al.  Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[170]  Manmohan J. Singh,et al.  Cationic microparticles: A potent delivery system for DNA vaccines. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[171]  L. Lunsford,et al.  Tissue Distribution and Persistence in Mice of Plasmid DNA Encapsulated in a PLGA-Based Microsphere Delivery Vehicle , 2000, Journal of drug targeting.

[172]  S. Schwendeman,et al.  Stabilization of proteins encapsulated in injectable poly (lactide-co-glycolide) , 2000, Nature Biotechnology.

[173]  A. Klibanov,et al.  Protein stability in controlled-release systems , 2000, Nature Biotechnology.

[174]  R. Steinman,et al.  Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. , 1999, Immunity.

[175]  Manmohan J. Singh,et al.  Advances in vaccine adjuvants , 1999, Nature Biotechnology.

[176]  A. Sette,et al.  Peptide vaccination using nonionic block copolymers induces protective anti-viral CTL responses. , 1999, Vaccine.

[177]  D. McDonald,et al.  Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. , 1999, Vaccine.

[178]  F. Sallusto,et al.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.

[179]  G. Schmid-Schönbein,et al.  Size- and surface-dependent uptake of colloid particles into the lymphatic system. , 1999, Lymphology.

[180]  Y. Barenholz,et al.  A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice. , 1999, Vaccine.

[181]  Kinam Park,et al.  Complement activation by PEO-grafted glass surfaces. , 1999, Journal of biomedical materials research.

[182]  J L Cleland,et al.  Development of a single-shot subunit vaccine for HIV-1. 5. programmable in vivo autoboost and long lasting neutralizing response. , 1998, Journal of pharmaceutical sciences.

[183]  H. Elwing,et al.  Complement activation and inflammation triggered by model biomaterial surfaces. , 1998, Journal of biomedical materials research.

[184]  A. Pombo,et al.  Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response. , 1998, Journal of immunology.

[185]  M. S. Singh,et al.  Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. , 1998, Advanced drug delivery reviews.

[186]  Gupta,et al.  Aluminum compounds as vaccine adjuvants. , 1998, Advanced drug delivery reviews.

[187]  E. Ingulli,et al.  Visualization of specific B and T lymphocyte interactions in the lymph node. , 1998, Science.

[188]  M. Reddish,et al.  Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses. , 1998, Bioconjugate chemistry.

[189]  A. V. Medvedev,et al.  The Tumor Necrosis Factor-Inducing Potency of Lipopolysaccharide and Uronic Acid Polymers Is Increased when They Are Covalently Linked to Particles , 1998, Clinical Diagnostic Laboratory Immunology.

[190]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[191]  K. Whaley,et al.  Antigen-releasing polymer rings and microspheres stimulate mucosal immunity in the vagina. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[192]  N. Goto,et al.  Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. , 1997, Vaccine.

[193]  M. Newman,et al.  Development of an adjuvant-active nonionic block copolymer for use in oil-free subunit vaccines formulations. , 1997, Vaccine.

[194]  R. Gupta,et al.  In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid. , 1996, Vaccine.

[195]  S. Davis,et al.  Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics , 1995 .

[196]  R. Germain,et al.  Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis , 1995, The Journal of experimental medicine.

[197]  G. Matyas,et al.  Murine IgG subclass antibodies to antigens incorporated in liposomes containing lipid A. , 1995, Immunology letters.

[198]  K. Mills,et al.  Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. , 1995, Vaccine.

[199]  P van Hoogevest,et al.  MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. , 1995, Pharmaceutical biotechnology.

[200]  J L Cleland,et al.  Development of a single-shot subunit vaccine for HIV-1. , 1997, AIDS research and human retroviruses.

[201]  P. Holt,et al.  Rapid dendritic cell recruitment is a hallmark of the acute inflammatory response at mucosal surfaces , 1994, The Journal of experimental medicine.

[202]  R. Zinkernagel,et al.  The influence of antigen organization on B cell responsiveness. , 1993, Science.

[203]  K. Rock,et al.  Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[204]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[205]  M. V. Van Regenmortel,et al.  Induction of immune response against a short synthetic peptide antigen coupled to small neutral liposomes containing monophosphoryl lipid A. , 1993, Molecular immunology.

[206]  B. Rouse,et al.  Induction of cytotoxic T lymphocytes in vivo with protein antigen entrapped in membranous vehicles. , 1992, Journal of immunology.

[207]  R. Langer,et al.  The pharmacokinetics of, and humoral responses to, antigen delivered by microencapsulated liposomes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[208]  C. Alving,et al.  Liposomes as carriers of antigens and adjuvants. , 1991, Journal of immunological methods.

[209]  G. Zlabinger,et al.  Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation. , 1985, Clinical and experimental immunology.

[210]  G. Scherphof,et al.  Transfer and exchange of phospholipid between small unilamellar liposomes and rat plasma high density lipoproteins. Dependence on cholesterol content and phospholipid composition. , 1981, Biochimica et biophysica acta.

[211]  T. Allen.  A study of phospholipid interactions between high-density lipoproteins and small unilamellar vesicles. , 1981, Biochimica et biophysica acta.

[212]  R. Langer,et al.  A single-step immunization by sustained antigen release. , 1979, Journal of immunological methods.

[213]  B. Vogelstein,et al.  Molecular determinants of immunogenicity: the immunon model of immune response. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[214]  R. White,et al.  Studies on antibody production. III. The alum granuloma. , 1955 .

[215]  W. T. Harrison.  Some Observations on the Use of Alum Precipitated Diphtheria Toxoid. , 1935, American journal of public health and the nation's health.

[216]  A. Glenny,et al.  Rate of Disappearance of Diphtheria Toxoid injected into Rabbits and Guinea-Pigs: Toxoid precipitated with Alum. , 1931 .